Patents by Inventor Michel Perez
Michel Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180228915Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: January 31, 2018Publication date: August 16, 2018Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
-
Patent number: 10047064Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.Type: GrantFiled: July 6, 2015Date of Patent: August 14, 2018Assignee: PIERRE FABRE MEDICAMENTInventors: Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
-
Publication number: 20180222858Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.Type: ApplicationFiled: September 19, 2017Publication date: August 9, 2018Applicant: PIERRE FABRE MEDICAMENTInventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
-
Publication number: 20180086729Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.Type: ApplicationFiled: December 1, 2017Publication date: March 29, 2018Applicant: PIERRE FABRE MEDICAMENTInventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
-
Publication number: 20170348808Abstract: A method for repairing a fan casing in which the inner surface is damaged, includes attaching a reinforcement element to the fan casing, the reinforcement element being attached to the outer surface of the fan casing opposite the damage.Type: ApplicationFiled: December 16, 2015Publication date: December 7, 2017Inventors: Antoine Patrice Marie DESREUMAUX, Patrick Jean-Louis REGHEZZA, Sébastien Marc Jean-Michel PEREZ
-
Patent number: 9669106Abstract: The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.Type: GrantFiled: October 26, 2015Date of Patent: June 6, 2017Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Alexandra Jouhanneaud, Michel Perez
-
Publication number: 20170137400Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.Type: ApplicationFiled: July 6, 2015Publication date: May 18, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
-
Publication number: 20170112943Abstract: The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.Type: ApplicationFiled: October 26, 2015Publication date: April 27, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Alexandra Jouhanneaud, Michel Perez
-
Publication number: 20170043032Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
-
Publication number: 20170043031Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Mathieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT
-
Patent number: 9462944Abstract: A surgical microscopy system comprises microscopy optics for generating an image of an eye under surgery. A pattern generator generates a pattern to be superimposed with the image. An eye-tracker is provided for tracking a position of the superimposed pattern with respect to the image in case of a movement of the eye. The superimposed pattern comprises pattern elements that are equally distributed on first and second circles of different sizes, in order to give assistance when placing a suture during a corneal transplant. The superimposed pattern may also provide an assistance for orientating a toric intra-ocular lens.Type: GrantFiled: March 4, 2011Date of Patent: October 11, 2016Assignee: CARL ZEISS MEDITEC AGInventors: Gerhard Moeller, Anja Seiwert, Michel Perez, Peter Amend
-
Patent number: 9416143Abstract: The present invention relates to compounds of the following general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to the uses thereof as a drug, in particular in the treatment of cancerous or precancerous hyperproliferative conditions, and to the pharmaceutical compositions containing same.Type: GrantFiled: August 1, 2013Date of Patent: August 16, 2016Assignee: PIERRE FABRE MEDICAMENTInventors: Frédéric Marion, Frédéric Lieby-Muller, Serge Grisoni, Nicolas Rahier, Michel Perez, Isabelle Sartori
-
Publication number: 20160083420Abstract: The present invention concerns a compound of following formula (I) where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: —an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or —a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.Type: ApplicationFiled: April 25, 2014Publication date: March 24, 2016Applicant: PIERRE FABRE MEDICAMENTInventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
-
Publication number: 20160068566Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ? a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ? —(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ? an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ? a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.Type: ApplicationFiled: April 25, 2014Publication date: March 10, 2016Applicant: PIERRE FABRE MEDICAMENTInventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
-
Publication number: 20160068567Abstract: The present invention concerns a compound of following formula (I) where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.Type: ApplicationFiled: April 25, 2014Publication date: March 10, 2016Applicant: PIERRE FABRE MEDICAMENTInventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
-
Patent number: 9187438Abstract: The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11?-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1,2,3,4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R?4 represent a hydrogen.Type: GrantFiled: March 2, 2010Date of Patent: November 17, 2015Assignee: PIERRE FABRE MEDICAMENTInventors: Michel Perez, Marie Lamothe, Didier Junquero, Yves Rival
-
Publication number: 20150210713Abstract: The present invention relates to compounds of the following general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to the uses thereof as a drug, in particular in the treatment of cancerous or precancerous hyperproliferative conditions, and to the pharmaceutical compositions containing same.Type: ApplicationFiled: August 1, 2013Publication date: July 30, 2015Applicant: PIERRE FABRE MEDICAMENTInventors: Frédéric Marion, Frédéric Lieby-Muller, Serge Grisoni, Nicolas Rahier, Michel Perez, Isabelle Sartori
-
Patent number: 8883821Abstract: The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.Type: GrantFiled: November 27, 2012Date of Patent: November 11, 2014Assignee: Pierre Fabre MedicamentInventors: El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot, Anna Kruczynski, Philippe Schmitt, Michel Perez, Nicolas Rahier
-
Patent number: 8513258Abstract: The present invention relates to compounds of general formula (I): wherein: R1 represents: halogen, CN or NO2; R2 represents: hydrogen or halogen; n represents: 1 or 2; R3 represents: phenyl substituted by one or more halogens or C1-C6 alkyls; or a cyclohexyl; as well as the therapeutically-acceptable salts or solvates thereof. These compounds are useful as protease-activated receptor-1 (PAR-1) antagonists, particularly in the treatment of thrombosis.Type: GrantFiled: May 21, 2012Date of Patent: August 20, 2013Assignee: Pierre Fabre MedicamentInventors: Michel Perez, Marie Lamothe, Bruno Le Grand, Robert Letienne
-
Patent number: 8486085Abstract: A surgical microscopy system comprises microscopy optics for generating an image of an eye under surgery. A pattern generator generates a pattern to be superimposed with the image. An eye-tracker is provided for tracking a position of the superimposed pattern with respect to the image in case of a movement of the eye. The superimposed pattern comprises pattern elements that are equally distributed on first and second circles of different sizes, in order to give assistance when placing a suture during a corneal transplant. The superimposed pattern may also provide an assistance for orientating a toric intra-ocular lens.Type: GrantFiled: March 4, 2011Date of Patent: July 16, 2013Assignee: Carl Zeiss Meditec AGInventors: Gerhard Moeller, Anja Seiwert, Michel Perez, Peter Amend